Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 46-50

  Wang, Chia Chi ^a,b   Tseng, Kuo Chih ^a,b   Peng, Cheng Yuan ^c   Hsieh, Tsai Yuan ^d   Lin, Chih Lin ^e   Su, Tung Hung ^f   Tseng, Tai Chung ^a,b   Hsu, Ching Sheng ^a,b   Lin, Hans Hsienhong ^a,b   Kao, Jia Horng ^f  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Alanine aminotransferase; Entecavir; Hepatitis B e antigens; Hepatitis B virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CORRELATION ANALYSIS; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY; VIRUS LOAD;

EID: 84871641910     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07269.x     Document Type: Article

References (21)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002; 2: 395-403.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-370.
3. Zhang QQ, An X, Liu YH etal. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol. J. 2011; 8: 72-82.
4. Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int. 2011; 31 (Suppl. 1): 117-121.
5. Lai CL, Yuen MF. Chronic hepatitis B-new goals, new treatment. N. Engl. J. Med. 2008; 359: 2488-2491.
6. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
7. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
8. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
10. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
11. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
12. Yokosuka O, Takaguchi K, Fujioka S etal. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J. Hepatol. 2010; 52: 791-799.
13. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B Patients: VIRAL suppression, viral resistance, and clinical safety. Am. J. Gastroenterol. 2011; 106: 1264-1271.
14. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
15. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
16. Liaw YF, Gane E, Leung N etal. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
17. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
18. Zeuzem S, Gane E, Liaw YF etal. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009; 51: 11-20.
19. Zoutendijk R, Reijnders JG, Brown A etal. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-451.
20. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-774.
21. Ridruejo E, Adrover R, Cocozzella D etal. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int. J. Clin. Pract. 2011; 65: 866-870.